Get a Quote
Receive a tailored pricing based on your needs.
- Choose license type
- Multiple user options
- Custom scope & coverage
- Fast turnaround
"Designing Growth Strategies is in our DNA"
The global small interfering RNA (siRNA) therapeutics market is witnessing substantial growth due to a rise in investment for research and development that advances treatments with enhanced delivery, stability, and efficacy of small interfering RNA. Small Interfering RNA represents a class of molecules capable of regulating gene expression and protein production. These molecules are designed to prevent the production of disease-causing proteins by targeting the messenger RNA (mRNA) that encodes for such proteins. Therapeutic small interfering RNAs (siRNAs) are double-stranded RNAs that silence genes by activating the RNA interference pathway (RNAi). These double-stranded RNAs allow the design of potent siRNAs for specific gene silencing.
A rise in investment and funding activities led to the development of numerous pipeline candidates to meet the rising demand. Due to such rising demand for small-interfering RNA therapeutics, many established players focus on strategic activities such as acquisition and collaboration to propel the market's growth.
Increasing Collaboration with the Operational Entities and Technological Advancement to Drive the Growth of the Market
The rising demand for personalized medicine and the need for effective alternative treatments resulted in effective siRNA therapies. To support this rising demand, various operational entities in the market are undergoing strategic activities such as collaboration and acquisitions. Such developments are expected to steer the market growth.
Furthermore, technology integration, such as machine learning and artificial intelligence, supports the market's growth.
Prevalence of Primary Hyperoxalurias (PH), By Type (% per million population)

In January 2020, Orphanet updated its report that stated the prevalence of Primary Hyperoxalurias (PH) ranges from 1 to 3 patients per 1,000,000 population. In which PH1 accounted for 85.0% of patients, PH2 8.0-10.0% and PH3 5.0-7.0%. Such a high incidence of PH1, which are treated with siRNA, is expected to support the growth of the market.
Off-Target Effects of Small Interfering RNA to Restrict Growth Potential
One of the major concerns in siRNA therapeutics is off-target effects and unintended gene expression. Often, clinical trials face failure due to off-target effects, such as off-target gene dysregulation. This could result in potential toxic side effects. These factors can restrict the growth of the market in the forecasted years.
Also, adverse effects associated with administering therapeutic siRNA molecules, such as injection site reactions, arthralgia, urinary tract infection, diarrhea, bronchitis, pain in the extremities, and dyspnea, could hamper the market growth.
Emergence of Combination Therapies Using Small Interfering RNA for the Therapeutic Treatment of Cancer to Offer Avenues for Market Growth
Integration of the siRNA therapeutics with other pharmacological modalities such as molecule drugs, antibodies, or even gene editing technologies, combining oligonucleotides, is part of the combination therapies. These advancements expand the application areas of siRNA therapeutics in various verticals such as infectious disease, cancer, and cardiovascular diseases. Research and development in the therapeutic application for siRNA offer greater expansion avenues for growth.
The report covers the following key insights:
| By Product | By Disease Indication | By Route of Administration | By Age | By Distribution Channel | By Region |
|
|
|
|
|
|
By product, the market is divided into Fitusiran, Patisiran, Givosiran, Lumasiran, Inclisiran, Vutisiran, and Others.
The inclisiran segment is expected to grow significantly in the forecast period of the global small-interfering RNA therapeutics market. The high market share of the product is attributed to recent marketing approvals by regulatory bodies.
By disease indication, the global small interfering RNA therapeutic market is classified into hereditary transthyretin amyloidosis (hATTR), acute hepatic porphyria (AHP), primary hyperoxaluria type 1 (PH1), clinical atherosclerotic cardiovascular disease (ASCVD), and others.
Among these, clinical atherosclerotic cardiovascular disease (ASCVD) is expected to hold a considerable position due to its high prevalence in comparison to other disease indications that utilize small interfering RNA for treatment. Additionally, many companies are investing profoundly in developing new therapies for the disease indication.
Based on route of administration, the small interfering RNA therapeutics are further divided into subcutaneous and intravenous, and others.
The subcutaneous segment is expected to grow substantially over the forecast period. Various research and development, along with new product launches, are being focused on the subcutaneous route of administration. Furthermore, regulatory approvals for subcutaneously administered siRNA therapeutics are also expected to support segmental growth.
Based on age, the market is further classified into pediatrics and adults. The adult segment is expected to hold a substantial market share. The high market share of the adult segment is attributed to the availability of numerous U.S. FDA-approved products.
By distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.
Hospital pharmacies are expected to hold a significant market share. The high market share of hospital pharmacies is expected due to increasing participation of hospital pharmacies in providing inpatient and outpatient care for patients.
By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.
Request for Customization to gain extensive market insights.
North America accounted for the largest share of the global small interfering RNA (siRNA) therapeutics market in 2024. The growth of the market in the region is attributed to the increasing number of clinical trials and ongoing research to boost the growth of the siRNA therapeutics market.
Moreover, marketing approvals by the various regulatory bodies in the region to drive the market growth in the forecasted years.
Europe is expected to grow with a considerable CAGR during the forecast period. The region's high market share is due to high investment in research initiatives. Many established players in the region are focusing on optimizing their product offerings and expanding the production capacity of small-interfering RNA to meet the rising demand in the region.
Asia Pacific is expected to grow with a substantial CAGR during the forecast period. The regional growth is attributed to the various strategic activities, such as commercialization agreements and collaboration within the operational entities in the region.
The global small-interfering RNA therapeutics market is semi-consolidated with the presence of a few groups and a large number of emerging companies.
The report includes the profiles of the following key players:
Get 30-60 hrs Free Customization
Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.
Get In Touch With Us
US +1 833 909 2966 ( Toll Free )
Receive a tailored pricing based on your needs.
Discuss your questions with our industry experts.
Have questions? Get quick answers before you purchase.